Updated Jul 16, 2026
Oliveto Joseph has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $556K.
Joseph Oliveto is the President and CEO of Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on developing etripamil for cardiovascular treatments. Under his leadership, the company is conducting clinical trials for innovative therapies in the field of cardiology.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-20 | MIST | Milestone Pharmaceuticals Inc. | S — Open-market sale | 36.5K | $2.26 | $82K |
| 2026-01-28 | MIST | Milestone Pharmaceuticals Inc. | S — Open-market sale | 34.5K | $1.93 | $67K |
| 2026-01-28 | MIST | Milestone Pharmaceuticals Inc. | M — Option exercise | 66.6K | — | |
| 2026-01-28 | MIST | Milestone Pharmaceuticals Inc. | S — Open-market sale | 133.1K | $2.32 | $309K |
| 2026-01-28 | MIST | Milestone Pharmaceuticals Inc. | A — Grant or award | 280.0K | — | |
| 2026-01-09 | MIST | Milestone Pharmaceuticals Inc. | S — Open-market sale [10b5-1] | 43.0K | $2.25 | $97K |
| 2026-01-09 | MIST | Milestone Pharmaceuticals Inc. | S — Open-market sale [10b5-1] | 500 | $2.25 | $1K |
| 2025-07-11 | MIST | Milestone Pharmaceuticals Inc. | A — Grant or award | 66.7K | — |
Joseph Oliveto is the President and CEO of Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on developing etripamil for cardiovascular treatments. Under his leadership, the company is conducting clinical trials for innovative therapies in the field of cardiology.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($556K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Oliveto Joseph profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.